Potential biomarker for screening nasopharyngeal carcinoma: three-microRNA panel in serum.

Background: Nasopharyngeal carcinoma (NPC) is a prevalent form of cancer in Southeast Asia, characterized by distinctive epidemiological attributes, and its occurrence is influenced by factors such as race, age, and gender. Prior research has highlighted the potential of serum microRNA (miRNA) profiling as a non-invasive biomarker for cancer detection. The objective of this study was to ascertain the miRNAs that are specifically linked to the diagnosis of NPC.

Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.

Background: The harm that prostate cancer inflicts on humans is becoming increasingly grave, imposing a tremendous burden and impact on patients and society. While PSA(Prostate-specific antigen) is commonly used for prostate cancer screening, its high rates of false positives and false negatives can lead to misdiagnosis (unnecessary prostate biopsies) or missed diagnoses (delayed treatment), with potentially serious consequences. Thus, there is a critical need for alternative diagnostic methods to overcome the limitations of PSA.

A panel of three serum microRNAs as a potential diagnostic biomarker for renal cell carcinoma.

Hitherto there is no praiseworthy noninvasive methods in the early diagnosis of renal cell carcinoma (RCC). MicroRNAs (miRNAs) could be utilized as molecular markers for diverse malignancies. In this study, we aim to discern potential miRNAs as markers for screening RCC.

Evaluation of the diagnostic value of a three-miRNA panel in prostate cancer: a discovery and validation study.

Background: PSA is widely used in prostate cancer screening. However, false-positive PSA results can lead to misdiagnosis and wrong puncture biopsy, while false-negative PSA results can result in missed diagnosis and delayed treatment. There is an urgent need to find convenient, economical and non-invasive diagnostic methods to reduce the false-negative and false-positive rates of PSA.

A three-miRNA panel in serum: Serving as a novel diagnostic method for nasopharyngeal carcinoma.

BackgroundNasopharyngeal carcinoma has unique epidemiological characteristics. Screening for this currently lacks a highly efficient, non-invasive, and inexpensive method. Serum microRNA (miRNA), which is stable and commonly present, has the potential to serve as a novel marker for nasopharyngeal carcinoma diagnosis.

Serum mature microRNA panel: A novel approach for primary prostate cancer diagnosis.

Background: Prostate cancer (PC) is the second most common malignant tumor in males and a leading cause of cancer-related morbidity and mortality among men. Early detection is essential for improving outcomes. Although prostate-specific antigen (PSA) is widely used for PC screening, it suffers from high false positive and false negative rates.

A panel based on three-miRNAs as diagnostic biomarker for prostate cancer.

Prostate cancer (PCa) is one of the most prevalent malignancies affecting the male life cycle. The incidence and mortality of prostate cancer are also increasing every year. Detection of MicroRNA expression in serum to diagnose prostate cancer and determine prognosis is a very promising non-invasive modality.

Testing the accuracy of a four serum microRNA panel for the detection of primary bladder cancer: a discovery and validation study.

Background: Bladder cancer (BC) is one of the ten most common cancers worldwide with late detection and early age of diagnosis. There is abundant evidence that early detection and timely intervention can lead to a better prognosis of BC. Substantial evidence has indicated that microRNAs (miRNAs) are specific to different tumour types and are remarkably stable, indicating that serum miRNAs may serve as potential cancer diagnostic markers.